3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Tumor-Agnostic
1
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
159
Carboplatin
147
Cisplatin
130
Pemetrexed
103
Paclitaxel
89
Nivolumab
71
Radiotherapy
69
Docetaxel
62
Erlotinib Hydrochloride
58
Gemcitabine
57
Etoposide
44
osimertinib
43
Bevacizumab
43
Cyclophosphamide
42
durvalumab
41
atezolizumab
35
Cetuximab
33
Radiosurgery
26
130-nm albumin-bound paclitaxel
26
fludarabine
23
Ipilimumab
23
Radiation
21
Magnetic Resonance Spectroscopy
21
Irinotecan
21
Taxes
20
Oxaliplatin
20
Fluorouracil
20
Gefitinib
19
Everolimus
19
Topotecan
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
rocakinogene sifuplasmid
×
Thoracic
×
Clear all
NCT02960594
2018-11-19
TRT-001
Inovio Pharmaceuticals
Phase 1
Completed
93 enrolled